Melinda S Schaller1, Greg J Zahner2, Warren J Gasper3, William S Harris4, Michael S Conte2, Nancy K Hills5, S Marlene Grenon3. 1. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA. Electronic address: melinda.schaller@ucsf.edu. 2. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA. 3. Department of Surgery, University of California, San Francisco, San Francisco, CA, USA; Department of Surgery, Vascular Surgery Section, Veterans Affairs Medical Center, San Francisco, CA, USA. 4. OmegaQuant Analytics, LLC, Sioux Falls, SD, USA; Department of Medicine, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, USA. 5. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Abstract
BACKGROUND:Oral supplementation with n-3 polyunsaturated fatty acids (PUFA) increases the omega-3 index, a biomarker of red blood cell eicosapentaenoic acid and docosahexaenoic acid, and plasma levels of biosynthesis pathway markers and potent lipid mediators involved in the resolution of inflammation among patients with peripheral arterial disease (PAD). OBJECTIVE: We aimed to quantify the association between an upstream change in the omega-3 index and downstream changes in lipid mediator production. METHODS: We conducted a secondary analysis of the OMEGA-PAD I Trial, a randomized, placebo controlled trial investigating high-dose n-3 PUFA oral supplementation in PAD patients. Eighty subjects were randomized to either 4.4 g of fish oil or placebo for 1 month. Regression analyses using generalized estimating equation techniques were used to investigate the relationship between changes in the omega-3 index and changes in lipid mediators, pre- and post-intervention. RESULTS: In the fish oil group, there was a significant increase in the omega-3 index (5 ± 1% to 9 ± 2%, P < .001) as well as in the plasma levels of several downstream lipid mediator pathway markers of resolution, which are involved with the regulation of leukocyte effector function and host defense. A doubling of the omega-3 index correlated with increases of 2.3-fold in 18-hydroxy-eicosapentaenoic acid (HEPE; P < .0001), 1.7-fold in 15-HEPE (P = .03), 1.9-fold in 5-HEPE (P = .04), and 3.6-fold in 4-hydroxy-docosahexaenoic acid (P < .001). CONCLUSION: Among subjects with symptomatic PAD who tookoral fish oil supplements for 1 month, observed changes in the omega-3 index were strongly associated with increases in downstream mediators in the biochemical pathways of resolution.
RCT Entities:
BACKGROUND: Oral supplementation with n-3 polyunsaturated fatty acids (PUFA) increases the omega-3 index, a biomarker of red blood cell eicosapentaenoic acid and docosahexaenoic acid, and plasma levels of biosynthesis pathway markers and potent lipid mediators involved in the resolution of inflammation among patients with peripheral arterial disease (PAD). OBJECTIVE: We aimed to quantify the association between an upstream change in the omega-3 index and downstream changes in lipid mediator production. METHODS: We conducted a secondary analysis of the OMEGA-PAD I Trial, a randomized, placebo controlled trial investigating high-dose n-3 PUFA oral supplementation in PAD patients. Eighty subjects were randomized to either 4.4 g of fish oil or placebo for 1 month. Regression analyses using generalized estimating equation techniques were used to investigate the relationship between changes in the omega-3 index and changes in lipid mediators, pre- and post-intervention. RESULTS: In the fish oil group, there was a significant increase in the omega-3 index (5 ± 1% to 9 ± 2%, P < .001) as well as in the plasma levels of several downstream lipid mediator pathway markers of resolution, which are involved with the regulation of leukocyte effector function and host defense. A doubling of the omega-3 index correlated with increases of 2.3-fold in 18-hydroxy-eicosapentaenoic acid (HEPE; P < .0001), 1.7-fold in 15-HEPE (P = .03), 1.9-fold in 5-HEPE (P = .04), and 3.6-fold in 4-hydroxy-docosahexaenoic acid (P < .001). CONCLUSION: Among subjects with symptomatic PAD who took oral fish oil supplements for 1 month, observed changes in the omega-3 index were strongly associated with increases in downstream mediators in the biochemical pathways of resolution.
Authors: Christine M Albert; Hannia Campos; Meir J Stampfer; Paul M Ridker; JoAnn E Manson; Walter C Willett; Jing Ma Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Christian A Hudert; Karsten H Weylandt; Yan Lu; Jingdong Wang; Song Hong; Axel Dignass; Charles N Serhan; Jing X Kang Journal: Proc Natl Acad Sci U S A Date: 2006-07-17 Impact factor: 11.205
Authors: Ramin Farzaneh-Far; Jue Lin; Elissa S Epel; William S Harris; Elizabeth H Blackburn; Mary A Whooley Journal: JAMA Date: 2010-01-20 Impact factor: 56.272
Authors: Nan Chiang; Gabrielle Fredman; Fredrik Bäckhed; Sungwhan F Oh; Thad Vickery; Birgitta A Schmidt; Charles N Serhan Journal: Nature Date: 2012-04-25 Impact factor: 49.962
Authors: Joel L Ramirez; Greg J Zahner; Kimberly A Spaulding; Sukaynah A Khetani; Nancy K Hills; Warren J Gasper; William S Harris; Beth E Cohen; S Marlene Grenon Journal: Lipids Date: 2019-03-18 Impact factor: 1.880
Authors: Imelda Ontoria-Oviedo; Elena Amaro-Prellezo; Delia Castellano; Elena Venegas-Venegas; Fernando González-Santos; Amparo Ruiz-Saurí; Beatriz Pelacho; Felipe Prósper; María Dolores Pérez Del Caz; Pilar Sepúlveda Journal: Int J Mol Sci Date: 2022-08-31 Impact factor: 6.208